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MoDE OF ACTION OF ANNEXIN V (VASCULAR ANTICOAGULANT ALPHA), A
PROTEIN SYNTHESIZED BY THE VESSEL WALL
Rein van Gooll, Harry A-M. Andree2,
Reutelingsperger 1 "
H. Coenraad Hemkerl, and Chris P.M.
Department of Biochemistryl and Research lnstitute for Cardiovascular Diseas€s2, University of
Limburg, Maastricht, the Netherlands
INTRODUCTION
Negatively charged phospholipids play a mandatory role in the coagulation process in that they
serve as an essential integral part of the procoagulant enzyme complexes formed by vitamin K-
dependent coagulation factors and tissue factor (1)'
Binding of the coagulation factors to the phospholipid surface improves the kinetic parameters of
the procoagulant reaction such that it proceeds readily under blood plasma conditions (2'3)'
Annexin v (formerly vascular anticoagulant alpha) was first discovered in a particular Protein
fraction of an arterial tissue homogenate as a consequence of iS pronounced anticoagulant
activity (4). Its mechanism of anticoagulation appeared to be distinct from those of the at that
time known anticoagulants like antithrombin lll/heparin and activated protein C' In contrast to
these annexin V showed no direct effect on the coagulation factors Per se but interfered with the
participation of negatively charged phospholipids in the procoagulant process (5).
Molecular cloning of irs cDNA (6) revealed annexin V to be identical to Placental antiooagulant
protein (7), endonexin II (8), PP4 (9), lipocortin V (10) and calphobindin (11)'
The deduced primary structure of annexin V showed an organisation in a 4-fold rePeat of a 67/6
amino acid long conserved sequence, containing a consensus first described for a number of
" C.p.M. Reutelingsperger was supported by a research grant from the Royal Dutch Academy of
Sciences (KNAW).
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C:2+-dependent membrane binding proteins (12). This structural feature defined a new family of
calciumiphospholipid binding proreins named rhe annexins (13).
Up to date eight different annexins have been discovered and their primary structures have been
elucidated by means of protein sequencing or cDNA cloning techniques (for refs. of annexin I-VI
see 10, annexin VII (14) and annexin VIII  (15)).
Next to the accumulated chemical information a number of biological activities have been
established for the annexins e.g. anicoagulant (4,6,15-18), anti-phospholipase activity
(10,15,19,20), membrane-cytoskeleton linkage (21) and exocytosis (22,23). All the.se biological
activities are based on the calcium/phospholipid binding properties and seem to be common
features of the annexins. However, the individual annexins exhibit different specific activities and
require different Ca2*-levels for membrane binding suggesting a diversification of physiological
functions.
Despite all the elaborated knowledge no clear picture of the true physiological functions of the
annexins exists as yet.
MATERaLS AND METI]jDS
hotein
Annexin V was prepared by cDNA recombinant techniques with plasmid pRH291 and purified as
described before (6). The protein preparation was more then99Vo prure.
Lipids
Dioleoyl-phosphatidylcholine (DOPC), dioleoyl-phosphatidylserine (DOPS), dioleoyl-phospha-
tidylglycerol (DOPG), dioleoyl-phosphatidylinositol (DOPI), dioleoyl-phosphatidylethanolamine
(PE), cardiolipin (CL) and sphingomyelin (SPH) were purchased from Sigma.
Annerin V binding to phospholipids
Adsorption of annexin V to phospholipid bilayers was studied using an auromated ellipsometer as
described in detail elsewhere (24).
Antibodies
Monospecific antibodies against annexin V were raised in rabbits employing standard techniques'
The antibodies were affinity puritied by using annexin V immobilized on Immobilon-P
membranes (MiliPore)
Swine anti-rabbit IgG conjugated with horse radish peroxida$e or fluorescein were products of
Dakopatts.
Cell culture
Endothelial cells (HUVEC) were isolatcd from human umbilical cord veins using established
techniques. The isolated cells were cultured on fibronectin coated culture plastics in RPMI 1640'
containing 2OVo humanserum, 2 mM L-glutamine and streptomycine/penicilline' When the cells
reached confluence they were passaged wing0'25V" trypsin in PBS'
Westem anatysis of enlothelial fractions
confluenr HUVEC were mllected with a policeman in 10 mM Hepes/NaOH, 140 mM NaCl' 1
m M P M S F ' 0 . l m M l e u p e p t i n a n d 3 0 u M E G T A p H l . 4 . T h e c e l l s u s p e n s i o n w a s f r o o z e n a n d
thawn three times and subsequently homogenized using a Potter Elvejhem. The lysed suspension
was adjusted to rhe desired ca2* concentration and then centrifuged for 30 min at 100,000 x g'
The supernatant was made 47o of sodium doderyl sulfate (sDS) and 5 mM 2-mercaptoethanol
(+sH).Thepelletwaswashedandfinal lysuspendedinSDS/+SH-buffer.
Protein samples were submitted to SDS-gelelectrophoresis under reducing conditions according
to l-aemmli (25). The separated proteins were then transferred from the gel into nitrocellulose
shees (BioRad) using the technique as described by Towbin et al. (26). Annexin V was stained by
indirect immunochemistry using anti-annexin v antibodies and peroxidase conjugated anti-IgG
antibodies.
Immunofluorescence
HUVEC of the second passage were seeded (8.104 cells/ml) on gelatin coated glass coverslips and
allowed ro attach for 24 hours in RPMI l64O,20Vo serum. The cells were washed with phosphate
buffered saline (PBS, 1.5 mM KH2Po4,6.5 mM Na2HPo4, 23 mM Kcl, 137 mM NaCl' pH 7'4)
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and subsequently treated the following procedure. Cells were fixed by a 25 minutes incubation
with3.5vo formaldehyde in l0 mM Hepes, 150 mM Nacl, pH 7.4 with or wirhout z mM c-acl2.
Subsequently the fixed cells were either used for immunofluorescen@ directlv or first
permeabilized by an incubarion with 0.5% Triton X-100 in pBS.
Annexin V in the obtained cell preparations was visualizedL,by indirect immunofluorescent
staining using the affinity purified monospecific antibodies. Control experiments comprised either
no anti-annexin V antibodies or antibodies, that were neutralized by purified annexin V.
Annexin V synthesis by HUWC
A confluent layer of HUvEc was washed with Methionine-free MEM, containing 2 mM L-
glutamine and 47o human serum. Endogenous methionine was depleted by a 6 hours incubation
of HUVEC in the latter medium. Then 35S-methionine was added and the incubation was
prolonged for anothei24 hours. In experiments where protein and RNA synthesis was blocked,
cycloheximide (10 ygml) and actinomycinc D (10 f/ml) was added respectively, 3 hours prior to
35S-methionine addir ion.
Following the incubation with labelled methionine the cells were washed and subsequently lpis of
the cells was provoked by rhe addilion of l1'sis buffer (10 mM Tris/FICl,300 mM NaCl, 1Zo Triton
X-100, 1.5 mM PMSF,0.1 mM leupeprin, 20 ug/ ml soybean trypsin inhibiror, 2 mM EDTd pH
7.4). For immunoprecipitation ofannexin V the lysed suspcnsion was incubated at 4oC overnight
with anti-annexin V conjugated to Sepharose beacls. These beads were then washed thoroughly
and subsequently suspended in an equal volume of 4vo sDS,5 mM 2-mercaptoethanol, 1.25 M
Tris/HCl pH 6.8 and submirted ro SDS-gel electrophoresis.
1. For qualitative analpis Western blotting was performed as described. The nitrocellulose sheet
was firstly autoradiographed and secondly stained for annexin V with indirect immunochemistry
using the peroxidase method.
2. For quantitative analysis the proteins in the gel were visualized with CuCl2 and the annexin V
band was excised and solved in Biofluor. Radioactivity was determined and the number of annexin
V molecules was calculated, knowing that each moleculc contains 8 residues of methionine.
t40
RESULTS AND DISCUSSION
Phospholipid binding ofannerin V
Annexin v does nor associate with a phospholipid surface in the absence of caz+ $,24). The
presence of 3 mM Ca2+ induces a rapid adsorption of annexin V to a negatively charged
phospholipid surface (fig. t). The rate of adsorption is limited by the transporr rate of annexin V
to the surface and is directly proportional to annexin V-concentration. This is the case until X)Vo
of the maximal adsorption is reached (24), indicating a high afiinity binding. The association is
completely reversible upon the addition of 3.5 mM EDTA Repeated adsorption and desorption
can be provoked by repeatedly alternating high and low Ca2*-levels (fig. 1). Adorption kinerics
o.3 0
+ Gact, ? EDTA
o.2 0
o.1 0
o.oo
I 12 15
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Fig. 1. Repeated adsorption and desorption of annexin V.
Adsorption of annexin v (ug/ml) to Ev" Psnsvo pc surface. Addition of caz+ 13,
4, 6 mM) and EDTA (3.5,4.5,, 10 mM) is indicated by the amow and arrowhead
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Fig.2. Binding isotherms of annexin V.
Binding of various annexin v concentrations to birayers of rffivo ps and zovo
Pilffi% PC is determined at 3 mM Ca2+
do not point to an irreversible change in annexin v binding properties as a oonsequence of the
oscillating ca2*-levels. This suggests a calcium-con(rolled physiological function of annexin v.
As discussed below our current knowledge implicates this function to be exhibited at extracellular
Ca2*-concentrations.
In order to assess the dissociation constant (k$ of annexin v binding isotherms were construcred
for adsorption to a zovo PS/8ovo PC and a loovo PS surface $g. z). wirhin the concentrarion
range tested the surface coverage always exceeded 507o, indicating a k4 < 10-10 M. since
adsorption times increased dramatically at low annexin v levels no k6-determination berter than
the above given estimation was practiarble.
There exists a ca2+ requirement for annexin v binding to phospholipid surfaces. This
requtrement appears to depend on the nature of the phospholipid surface and is reverselv related
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Fig .3 . The influence of Ca2+ conc€ntralion on the adsorption of annexin V to various
surfaces.
All mixtures are supplemented with PC. [Annexin V]= I lg/ml
to the PS contents (fig. 3). For binding to the optimal surface (100% PS) annexin V needs
approximately 0.04 mM Ca2+ to cover the surface half maximally. This demand of Ca2+
increases to 0.22 and 1.5 mM when PS mntents decreases to 207o and SVo respectively. Thus,
annexin V binding to PS containing surfaces is unlikely to occur at intracellular Ca2+-conditions
but readily takes place at blood plasma Ca2+ levels if annexin V concentration is above 10-10 M.
Although the binding of annexin V is stimulated by the presence of PS (fig. 4), the binding is not
specific for this phospholipid. Cardiolipin (CL), phosphatidylglycerol (PG), phosphatidylinositol
(PI), phosphatidylethanolamine (PE), sphingomyelin (SPH) and phosphatidylcholine (PC) all
induce annexin V binding (fig. 4). However, Ca2+ requirement for half-maximal binding to these
surfaces is distinct and is 0.M, 0.16,0.47,0.86,7 and > 30 mM, respe€tively.
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Fig.4. Adsorption of annexjn v ro phospholipid bilayers tif var,.rou; compositior..
Annexin v adsorption ro phospharidylserine (ps), cardiolipin (cL),
phosphatidylglyccrol (PG), phosphatidylinositol (PI), phosphatidylethanolamine
(PE), sphingomyeline (SPH), a[ mixed wirh ffi% pC. and IOOVo
phosphatidylcholine (PC). [Annexin Vj=t yg/ml, [Cu2+]=3 *M
Anticoagulant mechankm of annexin V
The afftnity of annexin V for a negatively charged phospholipid surface is a few orders of
magnitude higher than those of factor Xa (27,?3) and prothrombin (29). Even compared to factor
Va and factor Xa-Va complex (28,30) annexin V binds better to a procoagulant phospholipid
surface (fig. 5). In a competitive model it would implicate that annexin V displaces coagulation
fac(ors from the phospholipid surface. This, indeed, has been demonstrated for the proteins of the
prothrombinase complex (5,31, Andree manuscript in prep.).
It is likely that annexin V also competes efficiently with the phospholipid binding of the
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Immunoprecipitarion of metabolicaily labelled endothelial annexin v.
35s-methionine labbeiled endothelial proteins are immunoprecipitated with anti-
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uglml, [cycloheximide] = 16 p9r.1
coagulation factors constituting the other phospholipid dependent procoagulant complexes
(6,32,33).
Hence, annexin v is a novel anticoagulant interfering through a new mechanism on the
phospholipid dependent procoagulant reactions and completes the set ofanticoagulants acting on
the four component procoagulant complex (ng. 6).
The phospholipids which promore annexin V binding most srrongry are located in the
intracellular leaflet of the plasma membrane (34) and are exposed to blood plasma components
following activation of Platelets or endothelial cells, or cell damage. The then prevailing Ca2+
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concentrations will induce sequestration of these phospholipids from the coagulation system by
annexin V coverage if annexin V concentration exceeds 10-10 M.
Annqin V synthesis by endothelial cells
Northern blot analysis of total RNd isolated from HUVEC demonstrates the presence of
annexin V mRNA (not shown). Pulse-chase studie#using 3sS-methionine show rhar confluent
HUVEC (approximately 95Vo of the cells are in G0/Gl) synrhesize annexin V (fig. 7). Synthesis is
not affected by actinomycine D, indicating a stable mRNd at least in the presence of
actinomycine D, bul is completely blocked by cycloheximide (fig. 7). Western analysis shows that
annexin V level is hardly influenced by cycloheximide within a period of 24 hours, suggesting a
low turnover of annexin v.
With a semi-quantitative western analysis and a specific functional assay for annexin V it was
determinedthat one endothelial cell contains (3.1 t 0.t.ld and (4.5 + 0.9).ld molecules of
annexin V respectively (not shown).
Localisation of annerin V in the end.othelial cell
The staining of endothelial cells with indirect immunolluoresence using anti-annexin V
antibodies appears to depend on the conditions of fuation. Formaldehyde fuation with
permeabilization leads to a diffuse cytoplasmic staining that changes into a granular one if Ca2*
is added to the frxative (ng. 8). During formaldehyde fixation endothelial cells respond vigorously
within the first minutes of exposure. Membrane shuffling and vacuolization are observed and the
annexin V positive granular structures (lig. 8A) are therefore difficult to identi$. The
experiments, however, confirm the extrapolation of the in vitro results, in respect to the
Ca2+/phospholipid binding properties, to in vivo situation.
Formaldehyde fixed cells, which are nor permeabilized, show a patchy staining (fig. gc). At the
moment it is unknown, whether this originates from an extracellular localisation, as is observed
for the avian counterpart of annexin V (35), or is an arrifact of the formaldehyde luation as an
incident of localised damage.
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Fig' 8' Indirect immunofluorcscencc of endothelial cells using anti-annexin V antibodies.
Endothelial cells are fixed with 3.5vo formaldehyde and either permeabilized
(A'B'D) with Triton X-lOo or not (c). Fixation is performed either in the presence
(AC) or absence (B) of 2 mM ca2+. conrrols (D) comprised anti-annexin v
antibodies which were neutralized with purified annexin V
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Fig. 9. Calcium dependent differential distribution of annexin V over the cellular
compartments.
Endothcl ial ccl ls arc lyscd and ccntr i fugcd in thc prcscnce of various Ca2*-
concentrations. Cltosol and membrane fractions are analyzed by Western blotting
using anti-annexin V antibodies
Fractionation of the endothelial cell at different Ca2* concentrations results in a CaL+-
dependent distribution of annexin V over the rytosol and the membrane fractions (fig. 9). Supra
intraceltular Ca2*-levels are required for detectable association of annexin V with the
membranes, which is in agreement with the in vitro observed phospholipid binding properties and
and the immunofluorescence data. Furthermore this argues against the presence of a cofactor in
confluent endothel ial cel ls promoting phospholipi<l binding of annexin V at intracel lular Ca2*
concentrations.
Conclusions
The presented results demonstrate that annexin V is abundantly present in the confluent
endothelial cell (approximarely O.2-0.47o f total cellular protein) and occurs within the cell as a
cytoplasmic phospholipid binding (anticoagulant) protein. Association with granular structures
requires supra-intracellular Ca2*-levels, which likely occurs upon cell damage. Annexin V then
2149
acts as an anticoagulant by segregating procoagulant phospholipids from the coagulation process.
Although not yet demonstrated unambiguously for the endothelial cells circumstantial evidence
accumulates that annexin V is secreted into the extracellular compartment (36) and is present in
blood plasma at a level of 5-10 nglml (37,38). This value may increase during myocardial
infarction and disseminated intravascular coagulation (3g). i
Together with the findings that annexin v acts in vivo as an antithromboticum (3g,40), a role for
annexin v in the hemostatic system as an element of the anticoagulant paracrine properties of the
endothelium becomes very likely.
Since annexin V lacks a signal sequence, the mechanism via which it is externalized is a very
challenging subject of future rescarch.
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